Drugs / PF-07826390
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06546553 | Sep 2024 → Oct 2025 | colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, ovarian carcinoma +1 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07826390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546553 ↗ |
| Route | Intravenous | “PF-07826390) as an IV infusion (given directly into a vein)” NCT06546553 ↗ |
| Target | LILRB1 | “targets the leukocyte immunoglobulin-like receptor, LILRB1” NCT06546553 ↗ |